Bisphosphonates Labels Should Discuss Duration Of Use, Advisory Panels Conclude
This article was originally published in The Pink Sheet Daily
Executive Summary
But members of FDA's Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees acknowledged the lack of definitive evidence on potential risks from long-term use of the osteoporosis drugs.
You may also be interested in...
Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off
A data monitoring committee’s early termination of a 16,000-patient Phase III study of Merck’s cap-K inhibitor odanacatib suggests the osteoporosis therapy could have a competitive profile. Drug will need to offer significant advantages to cut it in the crowded market already saturated with generics.
Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off
A data monitoring committee’s early termination of a 16,000-patient Phase III study of Merck’s cap-K inhibitor odanacatib suggests the osteoporosis therapy could have a competitive profile. The drug will need to offer significant advantages to cut it in the crowded market already saturated with generics.
Drug Safety Business: Start-Up With AERS Filter Eyes Bisphosphonate Events
A small start-up company has developed a technique to filter the data in FDA’s Adverse Events Reporting System (AERS) database, which it says provides a more accurate analysis of adverse event reports.